WO2011054995A3 - PROPHYLACTIC FLU VACCINES FROM VIRAL CAPSIDS OF BIRNAVIRUS CONTAINING THE M2e ANTIGEN OF THE FLU VIRUS - Google Patents

PROPHYLACTIC FLU VACCINES FROM VIRAL CAPSIDS OF BIRNAVIRUS CONTAINING THE M2e ANTIGEN OF THE FLU VIRUS Download PDF

Info

Publication number
WO2011054995A3
WO2011054995A3 PCT/ES2010/070716 ES2010070716W WO2011054995A3 WO 2011054995 A3 WO2011054995 A3 WO 2011054995A3 ES 2010070716 W ES2010070716 W ES 2010070716W WO 2011054995 A3 WO2011054995 A3 WO 2011054995A3
Authority
WO
WIPO (PCT)
Prior art keywords
flu
birnavirus
antigen
prophylactic
vaccines
Prior art date
Application number
PCT/ES2010/070716
Other languages
Spanish (es)
French (fr)
Other versions
WO2011054995A2 (en
Inventor
Thomas Zurcher
Cayetano Von Kobbe
Juan José BERNAL
Ignacio JIMÉNEZ TORRES
María VELA CUENCA
Ana Diaz Blazquez
Miguel Angel Llamas Matias
Diana Martin Lorenzo
Arcadio GARCÍA DE CASTRO
Original Assignee
Chimera Pharma, S. L. U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimera Pharma, S. L. U. filed Critical Chimera Pharma, S. L. U.
Publication of WO2011054995A2 publication Critical patent/WO2011054995A2/en
Publication of WO2011054995A3 publication Critical patent/WO2011054995A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

The invention relates to prophylactic vaccines for preventing flu in humans. The vaccines according to the invention are especially formed by chimeric pseudo-viral capsids of birnavirus containing the M2e antigen of the flu virus.
PCT/ES2010/070716 2009-11-06 2010-11-05 PROPHYLACTIC FLU VACCINES FROM VIRAL CAPSIDS OF BIRNAVIRUS CONTAINING THE M2e ANTIGEN OF THE FLU VIRUS WO2011054995A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200930968 2009-11-06
ESP200930968 2009-11-06

Publications (2)

Publication Number Publication Date
WO2011054995A2 WO2011054995A2 (en) 2011-05-12
WO2011054995A3 true WO2011054995A3 (en) 2011-06-30

Family

ID=43806896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2010/070716 WO2011054995A2 (en) 2009-11-06 2010-11-05 PROPHYLACTIC FLU VACCINES FROM VIRAL CAPSIDS OF BIRNAVIRUS CONTAINING THE M2e ANTIGEN OF THE FLU VIRUS

Country Status (1)

Country Link
WO (1) WO2011054995A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059168A2 (en) * 2011-10-21 2013-04-25 Research Development Foundation Espirito santo virus and methods for detecting and preventing infection with the same
CN103083656A (en) * 2011-10-27 2013-05-08 苏州科贝生物技术有限公司 Conjugate of influenza A virus conservative peptides M2e and virus-like particles, and application thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887412A1 (en) * 1997-05-26 1998-12-30 Akzo Nobel N.V. Recombinant birnavirus vaccine
WO2002088339A2 (en) * 2001-05-02 2002-11-07 Institut National De La Recherche Agronomique (Inra) Bursal disease virus-like particles
WO2007009673A1 (en) * 2005-07-15 2007-01-25 Consejo Superior De Investigaciones Científicas Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications
EP1752468A1 (en) * 2004-04-30 2007-02-14 Consejo Superior de Investigaciones Cientificas Method for the production of empty viral capsids in yeasts, said capsids comprising proteins derived from pvp2 of the virus that causes infectious bursal disease (ibdv)
WO2007020017A1 (en) * 2005-08-12 2007-02-22 Bionostra, S.L. Composition for bird immunization administered by aerosol
WO2009026465A2 (en) * 2007-08-21 2009-02-26 Dynavax Technologies Corporation Composition and methods of making and using influenza proteins
WO2009135518A1 (en) * 2008-05-09 2009-11-12 Chimera Pharma S.L.U. Chimeric fusion proteins and virus like particles from birnavirus vp2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0996717B1 (en) 1997-08-05 2005-12-07 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoprotective influenza antigen and its use in vaccination

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887412A1 (en) * 1997-05-26 1998-12-30 Akzo Nobel N.V. Recombinant birnavirus vaccine
WO2002088339A2 (en) * 2001-05-02 2002-11-07 Institut National De La Recherche Agronomique (Inra) Bursal disease virus-like particles
EP1752468A1 (en) * 2004-04-30 2007-02-14 Consejo Superior de Investigaciones Cientificas Method for the production of empty viral capsids in yeasts, said capsids comprising proteins derived from pvp2 of the virus that causes infectious bursal disease (ibdv)
WO2007009673A1 (en) * 2005-07-15 2007-01-25 Consejo Superior De Investigaciones Científicas Chimeric empty viral-like particles derived from the infectious bursal disease virus (ibdv), process for their production and applications
WO2007020017A1 (en) * 2005-08-12 2007-02-22 Bionostra, S.L. Composition for bird immunization administered by aerosol
WO2009026465A2 (en) * 2007-08-21 2009-02-26 Dynavax Technologies Corporation Composition and methods of making and using influenza proteins
WO2009135518A1 (en) * 2008-05-09 2009-11-12 Chimera Pharma S.L.U. Chimeric fusion proteins and virus like particles from birnavirus vp2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LETZEL TOBIAS ET AL: "Molecular and structural bases for the antigenicity of VP2 of infectious bursal disease virus", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 81, no. 23, 1 December 2007 (2007-12-01), pages 12827 - 12835, XP002514417, ISSN: 0022-538X, [retrieved on 20070919], DOI: DOI:10.1128/JVI.01501.07 *
REMOND M ET AL: "Infectious bursal disease subviral particles displaying the foot-and-mouth disease virus major antigenic site", VACCINE, ELSEVIER LTD, GB, vol. 27, no. 1, 1 January 2009 (2009-01-01), pages 93 - 98, XP025714114, ISSN: 0264-410X, [retrieved on 20081105], DOI: DOI:10.1016/J.VACCINE.2008.10.036 *
VAN LOON A A W M ET AL: "Alteration of amino acids in VP2 of very virulent infectious bursal disease virus results in tissue culture adaptation and attenuation in chickens", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 83, no. 1, 1 January 2002 (2002-01-01), pages 121 - 129, XP002514415, ISSN: 0022-1317 *

Also Published As

Publication number Publication date
WO2011054995A2 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
HRP20180706T1 (en) Chimeric influenza virus-like particles comprising hemagglutinin
PL2121011T3 (en) Vaccines including antigen from four strains of influenza virus
AP2012006075A0 (en) Production of polio virus at high titers for vaccine production.
IL210451A (en) Influenza virus immunizing epitope
WO2011103453A3 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
IN2014CN02114A (en)
BRPI0912285A2 (en) monoclonal antibodies having homosubtype cross-neutralizing properties against the h1 subtype influenza virus.
MX352478B (en) Norovirus capsid and rotavirus vp6 protein for use as combined vaccine.
LT2635257T (en) RABIES GLYCOPROTEIN VIRUS-LIKE PARTICLES (VLPs)
HK1203524A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses h3n2h2n2 b
ZA201401020B (en) Benzofuran compounds for the treatment of hepatitis c virus infections
EP2484378A4 (en) Hepatitis c virus vaccine composition
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
WO2014145245A3 (en) Methods and compositions for norovirus blockade epitopes
EP2897628A4 (en) Novel attenuated dengue virus strains for vaccine application
WO2012058493A3 (en) Recombinant hemagglutinin protein of influenza virus and vaccine containing the same
ZA201503036B (en) Chimeric vaccine antigens against hepatitis c virus
EP2484757A4 (en) Virus capable of expressing -galactose epitope, and method for production of vaccine
WO2011054995A3 (en) PROPHYLACTIC FLU VACCINES FROM VIRAL CAPSIDS OF BIRNAVIRUS CONTAINING THE M2e ANTIGEN OF THE FLU VIRUS
WO2014008475A3 (en) Compositions and methods related to viral vaccines
EP3247390A4 (en) Immunogenicity of an optimized synthetic consensus dna vaccine for porcine epidemic diarrhea virus
WO2009117736A3 (en) Avian virus vaccines and uses thereof
WO2014188212A3 (en) Treatment and prevention of malaria
TH1201001748B (en) The part that can produce the empty capsid of the virus.
TH112917B (en) Bind proteins and ELISA-blocking epitopes for the general detection of influenza virus, subtype H5.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10809272

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 10809272

Country of ref document: EP

Kind code of ref document: A2